• LinkedIn
SFL Regulatory Affairs & Scientific Communication Ltd.
  • About SFL
    • Why SFL
    • Team
    • Associations
    • History
    • Awards
    • Ethics
  • Services
    • Regulatory Affairs
    • Quality Assurance & GxP Compliance
    • Medical Affairs & Communication
    • Market Access & Reimbursement
    • Public Affairs & Regulatory Intelligence
    • Medical Devices, Combination Products and IVDs
    • Pharmacovigilance & Clinical Safety
    • Supply Chains of Medicines and Devices
    • Legal & Healthcare Compliance
    • Swiss Support
    • UK Support
    • Clinical Trials support
  • Clients
    • Testimonials
    • Cases
  • Trainings
    • Customized training
    • Webinars
  • News
    • News
    • Newsletter
  • Careers
  • Contact
  • Search
  • Menu Menu

SFL/Veristat joint webinar on “Orphan Drug Designation – The Considerations, The Rewards, and How They Differ Between The US and Europe”

Today, Julien Gaudias, Senior Director Regulatory Affairs, and David Berner, Associate Director Regulatory Affairs at SFL, a Veristat company, will join Veristat colleagues Mara Holinger, Vice President Regulatory Affairs, and Ellen Truitt, Regulatory Affairs Strategist, to speak about “Orphan Drug Designation – The Considerations, The Rewards, and How They Differ Between The US and Europe”. The webcast will be held on Wednesday, 26 October 2022 from 7:00 – 8:00 PM CET (1:00 PM – 2:00 PM ET). To learn more and register for free, please visit Veristat website or the RAPS website.

Switzerland – Main Office

SFL Regulatory Affairs & Scientific Communication GmbH
Aeschenvorstadt 52 | CH-4051 Basel
Email: office@sfl-services.com
Phone: +41 61 361 9443

© Copyright 2023 - SFL Regulatory Affairs & Scientific Communication GmbH | Terms and Conditions | Privacy Statement | Cookies Policy
Scroll to top